Together, these findings suggest that combination treatments that target more than one of these E3 ubiquitin ligases may have potentially additive/synergistic effects on PD-L1 degradation in cancer, allowing a more potent stimulation of anti-tumor immunity. Here, CD274 is linked to neoplasm.